Fintel reports that on November 28, 2025, HC Wainwright & Co. reiterated coverage of Travere Therapeutics (NasdaqGM:TVTX) ...
Renalys Pharma reports positive results from phase III study of sparsentan in Japanese patients with IgA nephropathy: Tokyo, Japan Friday, November 28, 2025, 13:00 Hrs [IST] Renal ...
Rio Tinto Group is planning to sell its US boron assets, which could be valued at up to $2 billion, according to a Bloomberg report on Wednesday.
Investor's Business Daily on MSN
Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025
Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, ...
Anti-APRIL antibody Voyxact (sibeprenlimab) has been approved by the US regulator to reduce proteinuria in adults with ...
Travere Therapeutics' market cap has more than doubled in six months, reflecting confidence in FILSPARI's role in treating ...
Renalys Pharma Announces Positive Topline Results From Phase III Study Of Sparsentan In Japanese Patients With Iga Nephropathy. – In a Phase 3 clinical study evaluating the efficacy and safety of ...
Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.
Michael Burry Shutters Scion Asset Management, Renews AI Bubble Warning With Lord of the Rings Meme (International Business ...
A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.
On Thursday, 13 November 2025, Travere Therapeutics (NASDAQ:TVTX) participated in the TD Cowen Immunology and Inflammation Summit. The company shared strategic updates on its kidney treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results